Literature DB >> 1533729

Presence of CD16 on endothelial cells in heart transplant rejection: an immunohistochemical study.

W B Tuijnman1, P L Wijngaard, D van Wichen, J G van de Winkel, P J Capel, H J Schuurman.   

Abstract

We studied the distribution of Fc gamma RIII (CD16) in human lymphoid and non-lymphoid tissue by immunohistochemistry and two-colour immunofluorescence. In all tissues except stomach, skin, muscle and heart, infiltrating cells were stained. In tonsil and thymus, the CD16 antibody CLBgran 1 labelled some cells with high endothelial morphology in T-cell areas. Two-colour fluorescence combination of CD16 and antibody to Von Willebrand factor confirmed the endothelial nature of the CLB gran 1-positive cells. Fc gamma RIII expression was also demonstrated by antibody CLBgran11, which detects a product of the Fc gamma RIII-B gene of only the NA1 haplotype. A series of 95 endomyocardial biopsies (EMB) taken after heart transplantation was evaluated for Fc gamma RIII expression. In 18 cases Fc gamma RIII was unambiguously detected on endothelial cells by CD16 antibody CLBgran1. There was a significant correlation between capillary CD16 expression and transplant rejection. We conclude that Fc gamma R expression on endothelium represents endothelial activation found in immunopathological and inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533729     DOI: 10.1111/j.1365-3083.1992.tb03256.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  2 in total

1.  Detection of Fcgamma receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma).

Authors:  L F Pan; R A Kreisle; Y D Shi
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

2.  An inhibitory receptor of VLRB in the agnathan lamprey.

Authors:  Fenfang Wu; Liyong Chen; Yong Ren; Xiaojing Yang; Tongzhou Yu; Bo Feng; Shangwu Chen; Anlong Xu
Journal:  Sci Rep       Date:  2016-10-20       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.